RB Capital Management LLC Purchases New Holdings in TransMedics Group, Inc. $TMDX

Key Points

• RB Capital Management LLC has acquired 2,988 shares of TransMedics Group, Inc. valued at approximately $201,000, as reported in their recent 13F filing.
• Several hedge funds have increased their stakes in TransMedics, with New York State Teachers Retirement System growing their ownership by 183.2%, now holding 21,949 shares valued at $1,477,000.
• Wall Street brokerages have raised their price targets for TransMedics Group, with Canaccord Genuity increasing its price objective from $129.00 to $142.00 and maintaining a "buy" rating.

RB Capital Management LLC bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,988 shares of the company's stock, valued at approximately $201,000.

A number of other large investors also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its position in TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares during the period. Biondo Investment Advisors LLC increased its position in shares of TransMedics Group by 8.6% during the first quarter. Biondo Investment Advisors LLC now owns 58,070 shares of the company's stock worth $3,907,000 after acquiring an additional 4,620 shares during the last quarter. AlphaQuest LLC increased its position in shares of TransMedics Group by 55.6% during the first quarter. AlphaQuest LLC now owns 1,288 shares of the company's stock worth $87,000 after acquiring an additional 460 shares during the last quarter. Capital Fund Management S.A. increased its position in shares of TransMedics Group by 100.4% during the first quarter. Capital Fund Management S.A. now owns 252,294 shares of the company's stock worth $16,974,000 after acquiring an additional 126,414 shares during the last quarter. Finally, Credit Agricole S A increased its position in shares of TransMedics Group by 116.0% during the first quarter. Credit Agricole S A now owns 24,079 shares of the company's stock worth $1,620,000 after acquiring an additional 12,929 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Morgan Stanley boosted their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Oppenheimer boosted their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Finally, Canaccord Genuity Group lifted their target price on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and an average price target of $123.00.

TransMedics Group Price Performance

TMDX traded down $4.96 during trading on Tuesday, reaching $110.00. The stock had a trading volume of 224,832 shares, compared to its average volume of 1,304,114. The firm has a market capitalization of $3.75 billion, a price-to-earnings ratio of 57.04 and a beta of 2.18. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $169.29. The stock has a 50 day moving average of $119.99 and a two-hundred day moving average of $103.59.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. During the same period in the previous year, the business earned $0.35 EPS. The company's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.00% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.